BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wintjens DSJ, Bogie RMM, van den Heuvel TRA, le Clercq CMC, Oostenbrug LE, Romberg-camps MJL, Straathof J, Stassen LPS, Masclee AAM, Jonkers DMAE, Sanduleanu-dascalescu S, Pierik MJ. Incidence and Classification of Postcolonoscopy Colorectal Cancers in Inflammatory Bowel Disease: A Dutch Population-Based Cohort Study. Journal of Crohn's and Colitis 2018;12:777-83. [DOI: 10.1093/ecco-jcc/jjy044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Halliday G, Porter RJ, Black CJ, Arends MJ, Din S. c-MET immunohistochemical expression in sporadic and inflammatory bowel disease associated lesions. World J Gastroenterol 2022; 28(13): 1338-1346 [DOI: 10.3748/wjg.v28.i13.1338] [Reference Citation Analysis]
2 Wijnands AM, Mahmoud R, Lutgens MWMD, Oldenburg B. Surveillance and management of colorectal dysplasia and cancer in inflammatory bowel disease: Current practice and future perspectives. Eur J Intern Med 2021;93:35-41. [PMID: 34481721 DOI: 10.1016/j.ejim.2021.08.010] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
3 Schønfeldt Troelsen F, Sørensen HT, Pedersen L, Erichsen R. Risk of a post-colonoscopy colorectal cancer diagnosis in patients with inflammatory bowel disease: a population-based cohort study. Endoscopy 2021;53:1023-33. [DOI: 10.1055/a-1322-6574] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Abdalla M, Herfarth H. Rethinking Colorectal Cancer Screening in IBD, Is It Time to Revisit the Guidelines? J Crohns Colitis 2018;12:757-9. [PMID: 29846543 DOI: 10.1093/ecco-jcc/jjy073] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Stjärngrim J, Ekbom A, Hammar U, Hultcrantz R, Forsberg AM. Rates and characteristics of postcolonoscopy colorectal cancer in the Swedish IBD population: what are the differences from a non-IBD population? Gut 2019;68:1588-96. [DOI: 10.1136/gutjnl-2018-316651] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
6 Li J, Zhou WX, Liu S, Zheng WY, Wang YN, Li JN, Ferraz JG, Qian JM, Gui XY. Similarities and differences in clinical and pathologic features of inflammatory bowel disease-associated colorectal cancer in China and Canada. Chin Med J (Engl) 2019;132:2664-9. [PMID: 31725457 DOI: 10.1097/CM9.0000000000000525] [Reference Citation Analysis]
7 Wood PL, Donohue MM, Cebak JE, Beckmann TG, Messias MCF, Credidio L, Coy CSR, Carvalho PO, Crotti S, D'Aronco S, Urso EDL, Agostini M. Reduced Plasma Levels of Very-Long-Chain Dicarboxylic Acid 28:4 in Italian and Brazilian Colorectal Cancer Patient Cohorts. Metabolites 2018;8:E91. [PMID: 30563293 DOI: 10.3390/metabo8040091] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
8 Yılmaz Ürün Y, Üstündağ Y. Post-colonoscopy colorectal cancer rates in the Swedish IBD and non-IBD population: Something missed or something faster? Turk J Gastroenterol 2019;30:860-2. [PMID: 31530534 DOI: 10.5152/tjg.2019.030919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]